Medexus FY26 net loss widens to US$2.4 million; revenue falls 8.31% to US$99.3 million

• Medexus posted fiscal Q1 2027 net revenue of US$28.6 million, up 16.26% from US$24.6 million a year earlier.
• Adjusted EBITDA (non-GAAP) rose 38.24% to US$4.7 million; net income held at US$0.5 million.
• Operating cash flow swung to a use of US$0.7 million from US$3.9 million provided in the prior-year quarter.
• GRAFAPEX generated FY2026 product-level net revenue of US$11.6 million; 75 institutions had purchased the drug as of June 30, 2026.
• Management highlighted GRAFAPEX as a key near-term growth driver, citing 80% adjusted gross margins versus 56%-59% for the broader portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medexus Pharmaceuticals Inc. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.